CA2542513A1 - Treatment of osteoarthritis - Google Patents

Treatment of osteoarthritis Download PDF

Info

Publication number
CA2542513A1
CA2542513A1 CA002542513A CA2542513A CA2542513A1 CA 2542513 A1 CA2542513 A1 CA 2542513A1 CA 002542513 A CA002542513 A CA 002542513A CA 2542513 A CA2542513 A CA 2542513A CA 2542513 A1 CA2542513 A1 CA 2542513A1
Authority
CA
Canada
Prior art keywords
side chain
compound
alkyl
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542513A
Other languages
English (en)
French (fr)
Inventor
Ian Alexander Shiels
David Fairlie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promics Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2542513A1 publication Critical patent/CA2542513A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002542513A 2002-10-16 2003-10-16 Treatment of osteoarthritis Abandoned CA2542513A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952086 2002-10-16
AU2002952086A AU2002952086A0 (en) 2002-10-16 2002-10-16 Treatment of osteoarthritis
PCT/AU2003/001373 WO2004035079A1 (en) 2002-10-16 2003-10-16 Treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
CA2542513A1 true CA2542513A1 (en) 2004-04-29

Family

ID=28795579

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542513A Abandoned CA2542513A1 (en) 2002-10-16 2003-10-16 Treatment of osteoarthritis

Country Status (6)

Country Link
US (2) US7659246B2 (https=)
EP (1) EP1575606A4 (https=)
JP (2) JP2006505555A (https=)
AU (2) AU2002952086A0 (https=)
CA (1) CA2542513A1 (https=)
WO (1) WO2004035079A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7410945B2 (en) * 2002-10-16 2008-08-12 The University Of Queensland Treatment of inflammatory bowel disease
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
CA2685875C (en) * 2007-05-01 2015-10-06 Hill's Pet Nutrition, Inc. Methods and compositions for diagnosing osteoarthritis in a feline
WO2009151634A1 (en) * 2008-06-12 2009-12-17 The Board Of Trustees Of The Leland Stanford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
CN105392803B (zh) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
US11918624B2 (en) 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders
CN114594780B (zh) * 2022-01-24 2024-11-12 国家康复辅具研究中心 主动型假脚控制方法和系统以及终端滑模控制器

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5702946A (en) * 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
US5935796A (en) * 1995-06-30 1999-08-10 The University Of Melbourne Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown
US6013764A (en) * 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
JP3626206B2 (ja) * 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
US5916898A (en) * 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
US7410995B1 (en) * 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7410945B2 (en) * 2002-10-16 2008-08-12 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
AU2003902743A0 (en) * 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides

Also Published As

Publication number Publication date
JP2011241224A (ja) 2011-12-01
JP2006505555A (ja) 2006-02-16
AU2003269609A1 (en) 2004-05-04
US20100267639A1 (en) 2010-10-21
EP1575606A1 (en) 2005-09-21
US7659246B2 (en) 2010-02-09
AU2003269609B2 (en) 2008-11-20
US20060234921A1 (en) 2006-10-19
AU2002952086A0 (en) 2002-11-07
WO2004035079A1 (en) 2004-04-29
EP1575606A4 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
US20100267639A1 (en) Treatment of osteoarthritis
US7579432B2 (en) Cyclic peptides as G-protein-coupled receptor antagonists
CA2695504C (en) Compositions and methods for treatment and prevention of osteoarthritis
US20090004264A1 (en) Methods for treating and ameliorating the symptons of inflammatory bowel diseases
WO2012002668A2 (en) Novel peptide and use thereof
TWI589594B (zh) 用以治療和/或預防自體免疫疾病和發炎疾病的短合成胜肽
US20250152665A1 (en) Mutant Peptides And Methods Of Treating Subjects Using The Same
WO2009120656A1 (en) Pharmaceutical for ocular indications
US20210386744A1 (en) Sildenafil for use in the treatment of osteoarthritis
JP2006528208A (ja) コンプリメント５ａ受容体阻害剤を使用する出血ショックの処置
US20070021329A1 (en) Treatment of hypersensitivity conditions
AU2003215446B2 (en) Use of C5a receptor antagonist in the treatment of fibrosis
AU2003266862B2 (en) Treatment of hypersensitivity conditions
AU2003269602B2 (en) Treatment of inflammatory bowel disease
WO2026025169A1 (en) Peptide derived from crotalphine, composition comprising the said peptide, its use and method to treat acute or chronic pain
CN116139247A (zh) 一类订书肽化合物在制备治疗肺纤维化的药物中的应用
AU2003266862A1 (en) Treatment of hypersensitivity conditions
AU2004238089A1 (en) Treatment of haemorrhagic shock using complement 5a receptor inhibitors
AU2003269602A1 (en) Treatment of inflammatory bowel disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141016